vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and CVR PARTNERS, LP (UAN). Click either name above to swap in a different company.
CVR PARTNERS, LP is the larger business by last-quarter revenue ($180.0M vs $168.4M, roughly 1.1× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 26.0%). Over the past eight quarters, CVR PARTNERS, LP's revenue compounded faster (16.4% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
CVR Partners, LP is a leading North American producer of nitrogen-based fertilizer products, primarily urea ammonium nitrate (UAN) and ammonia. It serves agricultural, industrial and commercial markets across the U.S. and Canada, delivering cost-effective, high-quality nutrient solutions for crop production and diverse industrial use cases.
ESPR vs UAN — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $180.0M |
| Net Profit | — | $49.9M |
| Gross Margin | — | 37.5% |
| Operating Margin | 50.6% | 32.0% |
| Net Margin | — | 27.7% |
| Revenue YoY | 143.7% | 26.0% |
| Net Profit YoY | — | 84.3% |
| EPS (diluted) | $0.32 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $180.0M | ||
| Q4 25 | $168.4M | $131.1M | ||
| Q3 25 | $87.3M | $163.5M | ||
| Q2 25 | $82.4M | $168.6M | ||
| Q1 25 | $65.0M | $142.9M | ||
| Q4 24 | $69.1M | $139.6M | ||
| Q3 24 | $51.6M | $125.2M | ||
| Q2 24 | $73.8M | $132.9M |
| Q1 26 | — | $49.9M | ||
| Q4 25 | — | $-10.3M | ||
| Q3 25 | $-31.3M | $43.1M | ||
| Q2 25 | $-12.7M | $38.8M | ||
| Q1 25 | $-40.5M | $27.1M | ||
| Q4 24 | — | $18.3M | ||
| Q3 24 | $-29.5M | $3.8M | ||
| Q2 24 | $-61.9M | $26.2M |
| Q1 26 | — | 37.5% | ||
| Q4 25 | — | 4.4% | ||
| Q3 25 | — | 37.0% | ||
| Q2 25 | — | 32.4% | ||
| Q1 25 | — | 29.7% | ||
| Q4 24 | — | 23.8% | ||
| Q3 24 | — | 14.7% | ||
| Q2 24 | — | 30.0% |
| Q1 26 | — | 32.0% | ||
| Q4 25 | 50.6% | -2.2% | ||
| Q3 25 | -11.4% | 31.0% | ||
| Q2 25 | 8.6% | 27.5% | ||
| Q1 25 | -34.0% | 24.2% | ||
| Q4 24 | -6.4% | 18.4% | ||
| Q3 24 | -31.0% | 8.8% | ||
| Q2 24 | 3.5% | 25.3% |
| Q1 26 | — | 27.7% | ||
| Q4 25 | — | -7.8% | ||
| Q3 25 | -35.9% | 26.3% | ||
| Q2 25 | -15.4% | 23.0% | ||
| Q1 25 | -62.2% | 19.0% | ||
| Q4 24 | — | 13.1% | ||
| Q3 24 | -57.2% | 3.0% | ||
| Q2 24 | -83.9% | 19.7% |
| Q1 26 | — | — | ||
| Q4 25 | $0.32 | $-0.98 | ||
| Q3 25 | $-0.16 | $4.08 | ||
| Q2 25 | $-0.06 | $3.67 | ||
| Q1 25 | $-0.21 | $2.56 | ||
| Q4 24 | $-0.14 | $1.73 | ||
| Q3 24 | $-0.15 | $0.36 | ||
| Q2 24 | $-0.33 | $2.48 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $128.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | — |
| Total Assets | $465.9M | $1.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $128.1M | ||
| Q4 25 | $167.9M | $69.2M | ||
| Q3 25 | $92.4M | $156.2M | ||
| Q2 25 | $86.1M | $114.4M | ||
| Q1 25 | $114.6M | $121.8M | ||
| Q4 24 | $144.8M | $90.9M | ||
| Q3 24 | $144.7M | $110.5M | ||
| Q2 24 | $189.3M | $47.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | $569.1M | ||
| Q3 25 | — | $569.1M | ||
| Q2 25 | — | $569.2M | ||
| Q1 25 | — | $569.3M | ||
| Q4 24 | — | $568.0M | ||
| Q3 24 | — | $547.7M | ||
| Q2 24 | — | $547.6M |
| Q1 26 | — | — | ||
| Q4 25 | $-302.0M | — | ||
| Q3 25 | $-451.4M | — | ||
| Q2 25 | $-433.5M | — | ||
| Q1 25 | $-426.2M | — | ||
| Q4 24 | $-388.7M | — | ||
| Q3 24 | $-370.2M | — | ||
| Q2 24 | $-344.2M | — |
| Q1 26 | — | $1.0B | ||
| Q4 25 | $465.9M | $969.5M | ||
| Q3 25 | $364.0M | $1.0B | ||
| Q2 25 | $347.1M | $998.0M | ||
| Q1 25 | $324.0M | $1.0B | ||
| Q4 24 | $343.8M | $1.0B | ||
| Q3 24 | $314.1M | $986.6M | ||
| Q2 24 | $352.3M | $959.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | 7.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $45.2M | $-21.6M | ||
| Q3 25 | $-4.3M | $91.7M | ||
| Q2 25 | $-31.4M | $24.1M | ||
| Q1 25 | $-22.6M | $55.4M | ||
| Q4 24 | $-35.0M | $12.8M | ||
| Q3 24 | $-35.3M | $86.7M | ||
| Q2 24 | $-7.2M | $8.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-45.2M | ||
| Q3 25 | — | $80.1M | ||
| Q2 25 | — | $18.4M | ||
| Q1 25 | — | $45.5M | ||
| Q4 24 | — | $-5.6M | ||
| Q3 24 | $-35.5M | $82.3M | ||
| Q2 24 | $-7.3M | $2.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | -34.5% | ||
| Q3 25 | — | 49.0% | ||
| Q2 25 | — | 10.9% | ||
| Q1 25 | — | 31.9% | ||
| Q4 24 | — | -4.0% | ||
| Q3 24 | -68.7% | 65.7% | ||
| Q2 24 | -9.9% | 1.8% |
| Q1 26 | — | 7.6% | ||
| Q4 25 | 0.0% | 18.0% | ||
| Q3 25 | 0.0% | 7.1% | ||
| Q2 25 | 0.0% | 3.4% | ||
| Q1 25 | 0.0% | 6.9% | ||
| Q4 24 | 0.0% | 13.1% | ||
| Q3 24 | 0.3% | 3.6% | ||
| Q2 24 | 0.1% | 4.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 2.13× | ||
| Q2 25 | — | 0.62× | ||
| Q1 25 | — | 2.04× | ||
| Q4 24 | — | 0.70× | ||
| Q3 24 | — | 22.78× | ||
| Q2 24 | — | 0.33× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
UAN
| Fertilizer sales | $166.1M | 92% |
| Other | $14.0M | 8% |
